CompletedInterventionalPhase 3Updated Mar 25, 2009
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis | NCT00486798 | Trialant
TerminatedInterventionalPhase 3Updated Dec 10, 2010
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
ClinicalTrials.gov ID
NCT00486798
Lead Sponsor
AstraZenecaINDUSTRY
Overall Status
Terminated
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Dec 10, 2010Estimated
Start Date
May 2007
Primary Completion Date
Aug 2007Actual
Completion Date
Aug 2007Actual
Brief Summary
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
Psychotic Disorders
Schizophrenia
Bipolar Disorder
Quetiapine
Rating Scales
Self Assessment Form
Blood and urine samples
Sleeping pattern
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
provision of written informed consent
male or female, aged 18-65 years
requirement of hospitalization and in need for antipsychotic treatment for an acute psychotic episode
able to swallow tablets from Day 1
Exclusion Criteria:
In-patients who are anticipated to be discharged before evaluation of the primary outcome variable at Day 5